News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,741 Results
Type
Article (40001)
Company Profile (249)
Press Release (664490)
Multimedia
Podcasts (58)
Webinars (14)
Section
Business (204272)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81134)
Employer Resources (172)
FDA (16246)
Job Trends (14886)
News (345489)
Policy (32604)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1438)
Antibody-drug conjugate (ADC) (151)
Approvals (16243)
Artificial intelligence (307)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (120)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (364)
Cancer (2851)
Cardiovascular disease (209)
Career advice (1681)
Career pathing (30)
CAR-T (184)
CDC (30)
Cell therapy (495)
Cervical cancer (22)
Clinical research (66827)
Collaboration (1011)
Company closure (3)
Compensation (686)
Complete response letters (21)
COVID-19 (2625)
CRISPR (56)
C-suite (321)
Cystic fibrosis (111)
Data (2978)
Decentralized trials (2)
Denatured (20)
Depression (59)
Diabetes (346)
Diagnostics (6421)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (135)
Drug pricing (120)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87437)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113723)
Executive appointments (845)
FDA (17885)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (927)
Gene editing (129)
Generative AI (22)
Gene therapy (371)
GLP-1 (779)
Government (4499)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3636)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (491)
Leadership (18)
Legal (7929)
Liver cancer (79)
Lung cancer (399)
Lymphoma (207)
Machine learning (11)
Management (58)
Manufacturing (381)
MASH (90)
Medical device (13456)
Medtech (13461)
Mergers & acquisitions (19574)
Metabolic disorders (845)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (31)
Neuroscience (2109)
NextGen: Class of 2025 (6516)
Non-profit (4488)
Now hiring (47)
Obesity (425)
Opinion (217)
Ovarian cancer (100)
Pain (104)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (295)
Patient recruitment (160)
Peanut (50)
People (57675)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20826)
Phase II (29439)
Phase III (21903)
Pipeline (1619)
Policy (197)
Postmarket research (2563)
Preclinical (8864)
Press Release (64)
Prostate cancer (139)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (454)
Real estate (5917)
Recruiting (66)
Regulatory (22618)
Reports (50)
Research institute (2325)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (156)
Series B (107)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (75)
Tariffs (57)
The Weekly (36)
Vaccines (779)
Venture capital (53)
Weight loss (255)
Women's health (46)
Worklife (16)
Date
Today (25)
Last 7 days (380)
Last 30 days (1789)
Last 365 days (31198)
2025 (16637)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38199)
Australia (6231)
California (7407)
Canada (2351)
China (669)
Colorado (320)
Connecticut (316)
Delaware (192)
Europe (82087)
Florida (1115)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (360)
Iowa (16)
Japan (226)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1019)
Massachusetts (5508)
Michigan (245)
Minnesota (448)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2066)
New Mexico (28)
New York (2082)
North Carolina (1077)
North Dakota (8)
Northern California (3260)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1609)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2768)
Tennessee (125)
Texas (1114)
United States (27465)
Utah (219)
Virginia (183)
Washington D.C. (72)
Washington State (629)
West Virginia (4)
Wisconsin (65)
704,741 Results for "codagenix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
JPM2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development
The executive spoke with Biospace about Codagenix’s nasal COVID-19 spray vaccine, the COVID market, and how the company fits into the broader infectious disease space.
January 9, 2024
·
3 min read
·
Tyler Patchen
Policy
Codagenix Announces BARDA Contract for Project NextGen Supporting Development of CoviLiv™ as an Intranasal COVID-19 Vaccine
Codagenix Inc. announced that the BARDA has entered into a contract with Codagenix to support the costs of a Phase 2b clinical study of CoviLiv™ for the prevention of symptomatic COVID-19 in people who have completed their primary approved/authorized COVID-19 vaccine series and their last COVID-19 vaccine was at least 3 months beforehand.
October 3, 2023
·
4 min read
Pharm Country
Codagenix Receives Additional Award from US Department of Defense to Advance Development of Dengue Vaccine
Codagenix Inc. today announced that the US Department of Defense (DoD), through the US Army Medical Research and Development Command and the US Army Medical Research Acquisition Activity, has awarded the Company $5.88 million to advance the development of its CodaVax-DENV, a tetravalent live attenuated dengue vaccine program.
October 24, 2023
·
3 min read
Pharm Country
Codagenix Announces Late-Breaking Presentation of Positive Clinical Immunogenicity Data For COVID-19 Vaccine Candidate CoviLiv™ at IDWeek 2023
Codagenix Inc. announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.
October 11, 2023
·
4 min read
Pharm Country
Codagenix Announces Presentation of Updated Preclinical CodaLytic™ Data at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Codagenix Inc. today announced the presentation of preclinical data for CodaLytic™, a codon-modified virus being developed for breast cancer immunovirotherapy, at the Society for the Immunotherapy of Cancer (SITC) 38th Annual Meeting being held virtually and in-person November 1-5, 2023 in San Diego, California.
October 26, 2023
·
2 min read
Business
Codagenix Announces Appointment of Kimber Poffenberger, Ph.D., as Chief Strategy Officer
Codagenix Inc. today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer.
March 28, 2023
·
2 min read
Genetown
Codagenix Announces Close of $25 million Extension of Series B
Codagenix Inc. today announced the completion of a $25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital.
February 15, 2023
·
3 min read
Drug Development
Codagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV Vaccine, CodaVax™- RSV, in a Pediatric Population
Codagenix Inc. today announced that it has initiated dosing in a pediatric Phase 1 study evaluating CodaVax™-RSV, a live-attenuated, intranasal vaccine candidate for the prevention of disease caused by respiratory syncytial virus (RSV).
May 10, 2023
·
4 min read
Business
Codagenix Announces Appointment of Paul Grint, MD, as Executive Chairman of its Board of Directors
Codagenix Inc. announced that Paul Grint, MD, has been appointed Chairman of the Board of Directors.
December 15, 2022
·
2 min read
Pharm Country
Codagenix Receives FDA Fast Track Designation for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax™-RSV
Codagenix Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV).
November 2, 2022
·
3 min read
1 of 70,475
Next
